Assessment of the economic efficiency of the anesthetic nefopam in therapy postoperative pain
Качественная клиническая практика, 2018 The purpose of this pharmacoeconomic analysis was to determine the drug Nefopam economic feasibility of its use for postoperative pain relief in terms of the health system of the Russian Federation.
D. Yu. Belousov +2 more
doaj
Budget impact of modern drugs for the treatment of schizophrenia: regional aspects
Качественная клиническая практика, 2018 The article presents the results of comparative pharmacoeconomic analysis of treatment of schizophrenia with antipsychotics of the first and second generation in Khabarovsk territory.
K. V. Krot +2 more
doaj
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia
Качественная клиническая практика, 2018 We conduct a comparative cost-effectiveness and budget impact analysis of atypical antipsychotics for the treatment of schizophrenia - sertindole versus quetiapine, paliperidone. The primary outcome of interest was rehospitalization rates.
I. S. Krysanov, V. Yu. Ermakova
doaj
Comparative pharmacoeconomical analysis of modern antidepressants in monotherapy
Качественная клиническая практика, 2018 Compare the cost effectiveness and budget impact of vortioxetine in monotherapy of depressive disorders with several other important antidepressants using pharmacoeconomic methods within context of Russian healthcare.
A. E. Cheberda +2 more
doaj
Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson’s disease
Качественная клиническая практика, 2018 Objective. Health economic expertise of pramipexole extended release monotherapy at early stages of Parkinson’s disease. Methods. An economic model was developed based on clinical studies to derive comparative information on the effectiveness, utility ...
D. Yu. Belousov, E. V. Afanasyeva
doaj
Clinical and economic analysis of biologic drugs in treatment of psoriasis
Качественная клиническая практика, 2018 Purpose. To evaluate the cost effectiveness of use of ustekinumab (Stelara®), infliximab (Remicade®) and adalimumab (Humira®) for treatment of moderate and severe psoriasis. Methods.
A. A. Kubanov +2 more
doaj
Pharmacoeconomic analysis of Cocarnit® complex as treatment for diabetic polyneuropathy
Качественная клиническая практика, 2018 Diabetic polyneuropathy (DP) occupies the third place among the most common neurological disorders, affecting a significant portion of diabetes patients, and is characterized by progressive lesions of nervous fibers.
D. Yu. Belousov, A. E. Cheberda
doaj
Pharmacoeconomic analysis of Xeomine® for treatment patients with focal dystonia
Качественная клиническая практика, 2018 Focal dystonia is a large group of diverse neurological syndromes characterized by significant muscular contractions, spasms, repetitive movements, and persistent pathological poses (which in turn often causes pain syndrome).
S. K. Zyryanov +2 more
doaj
Pharmacoeconomics of spastic cerebral palsy
Регуляторные исследования и экспертиза лекарственных средств, 2018 Cerebral palsy (CP) is one of the most widespread and socially significant neurological diseases that affect both various aspects of physical and psychoverbal development of children since birth and stages of their personal development and adaptation in ...
R. I. Yagudina +3 more
doaj
Comparative pharmacoeconomic analysis of Paclical® and Taxol® in Russian Federation
Качественная клиническая практика, 2018 Ovarian cancer is a severe oncological disease, characterized by relatively late detection and unfavorable course leading to significant mortality among affected patients. One of the most well-proven treatment strategies is combination of taxanes such as
A. E. Cheberda, D. Yu. Belousov
doaj